Expiratory flow limitation in a cohort of highly symptomatic COPD patients

Augusta Beech, Natalie Jackson, James Dean, Dave Singh

Research output: Contribution to journalArticlepeer-review

16 Downloads (Pure)

Abstract

The question addressed by the study
Small airway collapse during expiration, known as expiratory flow limitation (EFL), can be
detected using oscillometry and is associated with worse clinical outcomes in chronic
obstructive pulmonary disease (COPD).
This study investigated the prevalence of EFL in a cohort of highly symptomatic patients,
evaluated clinical and lung function characteristics of patients with EFL and studied the
repeatability of EFL over 6 months.
Materials/patients and methods
Seventy patients were recruited. Clinical characteristics and lung function metrics were
collected at baseline and 6 months. Impulse oscillometry (IOS) was used to detect presence of
EFL. Patients were defined as EFLHigh (ΔX5 ≥0.28 kPa/L/s); EFLIntermediate (ΔX5 0.1-
0.27kPa/L/s) and EFLNone (ΔX5 <0.1 kPa/L/s).
Results
EFLHigh was present in 47.8% of patients at baseline. ΔX5 showed excellent repeatability over
6 months (rho = 0.78, p<0.0001, ICC = 0.88), with the best repeatability observed in EFLNone
and EFLHigh patients (ICC = 0.77 and 0.65 respectively). Compared to EFLNone patients, EFLHigh
had a higher BMI, worse health-related quality of life and increased peripheral airway
resistance. EFLIntermediate was more variable over time with less severe physiological
impairment.
Answer to the question
Overall, these data indicate that EFLHigh is a common, and relatively stable, component of
disease pathophysiology in highly symptomatic COPD patients. EFLHigh was also associated
with worse quality of life and obesity.
Original languageEnglish
JournalEuropean Respiratory Journal Open Research
Volume8
Issue number2
Publication statusPublished - 2 Mar 2022

Keywords

  • COPD
  • Oscillometry
  • Expiratory Flow Limitation
  • Small Airway Disease

Fingerprint

Dive into the research topics of 'Expiratory flow limitation in a cohort of highly symptomatic COPD patients'. Together they form a unique fingerprint.

Cite this